JP2019512002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512002A5 JP2019512002A5 JP2018539317A JP2018539317A JP2019512002A5 JP 2019512002 A5 JP2019512002 A5 JP 2019512002A5 JP 2018539317 A JP2018539317 A JP 2018539317A JP 2018539317 A JP2018539317 A JP 2018539317A JP 2019512002 A5 JP2019512002 A5 JP 2019512002A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- seq
- acid sequence
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021153453A JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291143P | 2016-02-04 | 2016-02-04 | |
| US62/291,143 | 2016-02-04 | ||
| PCT/US2017/016407 WO2017136659A2 (en) | 2016-02-04 | 2017-02-03 | Humanized anti-cd3 antibodies, conjugates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153453A Division JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512002A JP2019512002A (ja) | 2019-05-09 |
| JP2019512002A5 true JP2019512002A5 (enExample) | 2020-03-26 |
| JP6951826B2 JP6951826B2 (ja) | 2021-10-20 |
Family
ID=59501004
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539317A Active JP6951826B2 (ja) | 2016-02-04 | 2017-02-03 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
| JP2021153453A Pending JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153453A Pending JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12252534B2 (enExample) |
| EP (1) | EP3411069B1 (enExample) |
| JP (2) | JP6951826B2 (enExample) |
| KR (1) | KR102891788B1 (enExample) |
| CN (1) | CN109069635B (enExample) |
| AU (1) | AU2017213886B2 (enExample) |
| CA (1) | CA3013463C (enExample) |
| ES (1) | ES2992761T3 (enExample) |
| WO (1) | WO2017136659A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968552B1 (en) | 2013-03-14 | 2020-03-11 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
| KR102891788B1 (ko) | 2016-02-04 | 2025-11-26 | 더 스크립스 리서치 인스티튜트 | 인간화 항-cd3 항체, 접합체 및 이의 용도 |
| EP3668898B1 (en) | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| KR101973060B1 (ko) * | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| CA3110647A1 (en) * | 2018-08-28 | 2020-03-05 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
| WO2020135804A1 (zh) * | 2018-12-29 | 2020-07-02 | 上海一宸医药科技有限公司 | 异源二聚体融合蛋白 |
| KR20210142638A (ko) * | 2019-02-22 | 2021-11-25 | 우한 이지 바이오파마 씨오., 엘티디. | Cd3 항원 결합 단편 및 이의 응용 |
| WO2020232165A1 (en) * | 2019-05-14 | 2020-11-19 | Qlb Biotherapeutics | Bispecific anti-cd3 x cd20 antibodies and uses thereof |
| BR112021023048A2 (pt) | 2019-05-21 | 2022-04-19 | Novartis Ag | Moléculas de ligação a cd19 e usos das mesmas |
| TWI841790B (zh) * | 2019-09-30 | 2024-05-11 | 大陸商和鉑醫藥（上海）有限責任公司 | 靶向cd3的抗體、雙特異性抗體及其用途 |
| EP4063387A4 (en) * | 2019-11-22 | 2023-08-02 | Nantong Yichen Biopharma. Co. Ltd. | PSMA ANTIBODIES AND ITS USE |
| TWI827807B (zh) * | 2020-02-26 | 2024-01-01 | 香港商潤俊（中國）有限公司 | 抗cd3抗體葉酸生物共軛物及其用途 |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| CA3187085A1 (en) | 2020-08-25 | 2022-03-03 | Manuel Baca | Multi-specific antigen binding molecules targeting hiv and methods of use |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| CA3228654A1 (en) * | 2021-08-09 | 2023-02-16 | Brian Rabinovich | Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| WO2024108032A2 (en) * | 2022-11-18 | 2024-05-23 | Jn Biosciences Llc | Anti-cd3 antibodies |
| CN120569191A (zh) | 2022-11-23 | 2025-08-29 | 乔治亚大学研究基金公司 | 用于增加免疫应答的组合物及其使用方法 |
| KR20240139569A (ko) * | 2023-03-13 | 2024-09-23 | 머스트바이오 주식회사 | 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| IL160993A0 (en) | 2001-09-21 | 2004-08-31 | Univ Tulane | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| US7122622B2 (en) | 2002-04-16 | 2006-10-17 | Biosynthema Inc. | Peptide compounds having improved binding affinity to somatostatin receptors |
| CA2523716C (en) | 2003-05-31 | 2014-11-25 | Micromet Ag | Human anti-human cd3 binding molecules |
| CN100477345C (zh) | 2004-03-30 | 2009-04-08 | 株式会社吴羽 | 非水电解质二次电池用负极材料、其制造方法、负极和电池 |
| CA2561686C (en) | 2004-03-31 | 2014-12-02 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| ES2856451T3 (es) * | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
| WO2007058725A2 (en) | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| JP2009520949A (ja) | 2005-11-16 | 2009-05-28 | アンブルックス，インコーポレイテッド | 非天然アミノ酸を含んでいる組成物および方法 |
| EP1968635B1 (en) | 2005-12-14 | 2014-09-17 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| CA2632832A1 (en) | 2005-12-30 | 2007-07-12 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| CN101384711A (zh) | 2006-01-19 | 2009-03-11 | Ambrx公司 | 具有经调节的免疫原性的非天然氨基酸多肽 |
| WO2008077079A1 (en) | 2006-12-18 | 2008-06-26 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| KR20090102838A (ko) | 2006-12-28 | 2009-09-30 | 암브룩스, 인코포레이티드 | 페나진 및 퀴녹살린 치환된 아미노산 및 폴리펩티드 |
| CA2696627C (en) | 2007-08-17 | 2016-09-27 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| EP2291659B1 (en) | 2008-05-13 | 2015-09-16 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| DK2337846T3 (en) | 2008-09-26 | 2018-03-12 | Ambrx Inc | NON-NATURAL AMINO ACID REPLICATION DEPENDENT MICROORGANISMS AND VACCINES |
| WO2012098238A1 (en) | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| ME03440B (me) * | 2011-05-21 | 2020-01-20 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
| ES2898854T3 (es) | 2011-05-27 | 2022-03-09 | Ambrx Inc | Composiciones que contienen, métodos que implican, y usos de derivados de dolastatina enlazados con aminoácidos no naturales |
| US9796754B2 (en) | 2011-05-27 | 2017-10-24 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| US10358492B2 (en) | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
| RU2015117393A (ru) | 2012-10-08 | 2016-12-10 | Роше Гликарт Аг | Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| WO2014131711A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| EP2968552B1 (en) | 2013-03-14 | 2020-03-11 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
| WO2014185985A1 (en) | 2013-05-14 | 2014-11-20 | Ambrx, Inc. | Novel polypeptide small molecule conjugates and their uses |
| PL3004106T3 (pl) | 2013-06-07 | 2018-01-31 | Rhizen Pharmaceuticals S A | Podwójne selektywne inhibitory kinaz pi3 delta i gamma |
| KR102357968B1 (ko) * | 2013-10-15 | 2022-02-03 | 더 스크립스 리서치 인스티튜트 | 키메라 항원 수용체 t 세포 스위치 및 이의 용도 |
| BR112016009919A2 (pt) | 2013-11-04 | 2017-12-05 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma |
| KR102357961B1 (ko) * | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| NZ726520A (en) | 2014-05-29 | 2018-12-21 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| US11091546B2 (en) | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
| KR102891788B1 (ko) | 2016-02-04 | 2025-11-26 | 더 스크립스 리서치 인스티튜트 | 인간화 항-cd3 항체, 접합체 및 이의 용도 |
-
2017
- 2017-02-03 KR KR1020187025472A patent/KR102891788B1/ko active Active
- 2017-02-03 US US16/074,600 patent/US12252534B2/en active Active
- 2017-02-03 CA CA3013463A patent/CA3013463C/en active Active
- 2017-02-03 ES ES17748229T patent/ES2992761T3/es active Active
- 2017-02-03 AU AU2017213886A patent/AU2017213886B2/en active Active
- 2017-02-03 JP JP2018539317A patent/JP6951826B2/ja active Active
- 2017-02-03 EP EP17748229.6A patent/EP3411069B1/en active Active
- 2017-02-03 CN CN201780024266.1A patent/CN109069635B/zh active Active
- 2017-02-03 WO PCT/US2017/016407 patent/WO2017136659A2/en not_active Ceased
-
2021
- 2021-09-21 JP JP2021153453A patent/JP2022023052A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512002A5 (enExample) | ||
| AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| CY1114851T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων | |
| JP2013530929A5 (enExample) | ||
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
| CY1118008T1 (el) | Πρωτεϊνες δεσμευσης ετεροδιμερους και χρησεις αυτων | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| JP2017518083A (ja) | ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物 | |
| JP2016538240A5 (enExample) | ||
| JP2005120106A5 (enExample) | ||
| CN102838663B (zh) | 定点突变和定点修饰的病毒膜蛋白、其制备方法及其应用 | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| NZ598770A (en) | Monoclonal antibodies | |
| Okochi et al. | Array-based rational design of short peptide probe-derived from an anti-TNT monoclonal antibody | |
| JP2013538791A5 (enExample) | ||
| NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| WO2019104155A3 (en) | Chemical probe-dependent evaluation of protein activity and uses thereof | |
| RU2015154792A (ru) | Выделенный антиген лейкоцидина Staphylococcus aureus, антитело, специфически связывающееся с субъединицей LukGH и способ определения связывания или токсичности двухкомпонентного цитолизина LukGH Staphylococcus aureus | |
| CO6382184A2 (es) | Proteinas fijadoras de receptores de interleukinas-21 |